Atara Biotherapeutics Stock Discussion

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

$Atara Biotherapeutics (ATRA.US)$ Should have a re-entry at 7.70

$Atara Biotherapeutics (ATRA.US)$ over 30 million cash in the books acccording to there 30th of June Financial report , will have additional extra cash of 36 million on 5 September from institutional investors and big pharma company by issuing them around 4 million shares at 8.25 $ , will further receive 20 million + 60 Million by Pierre Fabre Pharmaceuticals once FDA approves there EBV drug in Jan 2025 .
Should see increased acitivity soon as all these large investors have interest in this comp...

$Atara Biotherapeutics (ATRA.US)$
good buy

$Atara Biotherapeutics (ATRA.US)$ Atara Biotherapeutics Announces $36 Million Registered Direct Offering

$Atara Biotherapeutics (ATRA.US)$
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
Atara Biotherapeutics (Nasdaq: ATRA) has announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering, priced at $8.25 per share, represents a 15% premium to Atara's 7-day volume-weighted average price. Participants include existing top institutional investors and a new strategic investor from a large public biotechnology company. The proceeds wi...